In this edition, we look at the first FDA approval of an oral therapy for chronic spontaneous urticaria, and more.

Read the full coverage here:

FDA approves first oral therapy for chronic spontaneous urticaria

Denifanstat safe, effective in acne vulgaris treatment

FDA approves Zoryve cream 0.05% for pediatric atopic dermatitis

The 'Zoom boom' effect: Post-pandemic cost concerns for facial cosmetic procedures

References:

F Xiang, et al. Abstract #LBA-213. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 17-20, 2025; Paris.

Pecora V, et al. J Drugs Dermatol. 2025;doi:10.36849/JDD.9102.

Press Release

Press Release